Multivalent nanobodies for potent and broad neutralization of Staphylococcus aureus toxins.

Summary

This study engineers multivalent, multifunctional nanobodies that neutralize S. aureus alpha-hemolysin and superantigens with picomolar potency and protect mice from pneumonia and sepsis. Structural mapping by cryo-EM and AlphaFold3 informs epitope selection and guides construct design, yielding aerosolizable and Fc-fused formats with broad anti-toxin coverage.

Key Findings

• Generated high-affinity nanobodies against Hla, SEB, SEC, and TSST-1 with structural epitope definition by cryo-EM and AlphaFold3.
• Engineered multivalent formats (aerosolizable trimer; decameric Nb-IgG-Fc) achieving picomolar or better neutralization across key S. aureus toxins.
• Demonstrated protection in murine models of pneumonia and sepsis, indicating in vivo efficacy of the anti-toxin strategy.

Clinical Implications

While preclinical, these nanobody constructs could complement antibiotics by neutralizing major toxins driving shock and organ injury in S. aureus sepsis. Translation will require safety, pharmacokinetic, and delivery studies (including inhalation) followed by early-phase clinical trials.

Limitations

• Preclinical study without human safety or pharmacokinetic data.
• Potential immunogenicity and manufacturing complexity of multivalent constructs require evaluation.

Future Directions

Advance to GLP toxicology and pharmacokinetics, assess inhalation and systemic delivery, and initiate phase 1 trials targeting high-risk S. aureus bacteremia/pneumonia with toxin-driven shock.